“Anti-pollution” claims in cosmetic products
Nowadays, it is possible to find in the market several cosmetic products with claims like “anti-pollution protection”, “pollution shield”, “against pollution damage” and similar ones. But how can a company test and prove this type of allegations?


According to the European Cosmetics Regulation (EC) No. 1223/2009, “in the labelling, making available on the market and advertising of cosmetic products, text, names, trademarks, pictures and figurative or other signs shall not be used to imply that these products have characteristics or functions which they do not have”. 

Claims of cosmetic products have the goal to inform the users about the characteristics and qualities of those products. The Product Information File (PIF) of the cosmetic product should contain proof of the effects claimed for such cosmetic (when justified by the nature or the effect of the cosmetic product). 

The EU Commission Regulation (EU) No. 655/2013 lays down the common criteria for the justification of claims used in relation to cosmetic products. Its main goal is to guarantee a high level of protection for end users, in particular from misleading claims in relation to cosmetic products.  

Claims made about cosmetic products that are available in the EU market must also follow the provisions of Directive 2005/29/EC. The purpose of this Directive is to protect traders against misleading advertising and the unfair consequences thereof, as well as, to lay down the conditions under which comparative advertising is permitted. It also has the purpose to contribute to the proper functioning of the internal market and achieve a high level of consumer protection.


Air pollution poses a major threat to health and climate. The World Health Organization (WHO) states that 9 out of 10 people breath air containing high levels of pollutants. Inhaled or ingested pollutants can be distributed through the whole body through the systemic circulation. Pollutants may reach the superficial and deeper skin layers by transcutaneous and systemic routes, which makes the skin one of the main targets of these compounds.   

Pollution may cause a wide range of effects on the skin, e.g. allergy, dull complexion, dark spots, premature ageing (wrinkles), cancer and others. Pollutants may activate cutaneous metabolism and inflammatory pathways and induce oxidative stress (lowering the levels of antioxidants present). UV radiation is also a known source of oxidative stress and a main factor on skin ageing. 

The main goal of cosmetics when fighting pollution is to avoid the entrance of pollutants through the skin barrier, inhibit reactions on skin surface (e.g. sebum peroxidation) and to prevent or correct metabolic reactions in skin cells.  


These days, in vitro/ex vivo testing is crucial to prove “anti-pollution” properties and efficacy, and consequent cosmetic claims. The state of cells and tissues can be evaluated by quantifying important biomarkers. Examples of such biomarkers are the following: 

  • DNA damage markers;  
  • Lactic acid content; 
  • Antioxidant defence markers;  
  • Mitochondrial proteins;  
  • Inflammation mediators;  
  • Stress proteins;  
  • Antioxidant and detox enzymes;  
  • Lipid metabolism biomarkers; protease activity;  
  • Proteins associated with pigmentation;  
  • Adenosine triphosphate; 
  • Interleukin IL1a; 
  • Tissue oxygenation.  

For example, pollution stress (like cigarette smoke, heavy metals, volatile organic compounds, and others) can be applied directly in cell culture media or by spraying the pollutant on skin tissue in a chamber.  

In vivo testing, like skin barrier test or evaluation of lipid peroxidation of sebum on volunteers, may also be done to access anti-pollution efficacy of cosmetics. However, this is not common and is more difficult to perform and evaluate objectively. 

There are no international regulated or standardized and reproducible anti-pollution tests, as well as there is no agreement on which biomarkers are best to prove the efficacy of anti-pollution products. 

At the end, different factors need to be considered and the cosmetic company should choose the correct testing depending on the intended claims. Testing the right pollutant can be a tricky question and it is important to be suitable to the different factors inherent to the region (climate, most common pollutants, skin type, etc) where the cosmetic is marketed. 


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. 
  1. Commission Regulation (EU) No 655/2013 of 10 July 2013 laying down common criteria for the justification of claims used in relation to cosmetic products. 
  1. Directive 2005/29/EC of the European Parliament and of the Council of 11 May 2005 concerning unfair business-to-consumer commercial practices in the internal market. 


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »